- Home
- CGNT vs PHAR Comparison
CGNT vs PHAR Comparison
Compare CGNT & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- PHAR
- Stock Information
- Founded
- CGNT 2020
- PHAR 1988
- Country
- CGNT Israel
- PHAR Netherlands
- Employees
- CGNT N/A
- PHAR N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- CGNT Technology
- PHAR Health Care
- Exchange
- CGNT Nasdaq
- PHAR Nasdaq
- Market Cap
- CGNT 669.2M
- PHAR 587.5M
- IPO Year
- CGNT N/A
- PHAR N/A
- Fundamental
- Price
- CGNT $11.02
- PHAR $10.08
- Analyst Decision
- CGNT Hold
- PHAR Strong Buy
- Analyst Count
- CGNT 2
- PHAR 3
- Target Price
- CGNT $9.00
- PHAR $30.00
- AVG Volume (30 Days)
- CGNT 236.1K
- PHAR 3.5K
- Earning Date
- CGNT 06-17-2025
- PHAR 05-08-2025
- Dividend Yield
- CGNT N/A
- PHAR N/A
- EPS Growth
- CGNT N/A
- PHAR N/A
- EPS
- CGNT N/A
- PHAR N/A
- Revenue
- CGNT $350,632,000.00
- PHAR $320,708,000.00
- Revenue This Year
- CGNT $13.87
- PHAR $13.31
- Revenue Next Year
- CGNT $9.64
- PHAR $7.68
- P/E Ratio
- CGNT N/A
- PHAR N/A
- Revenue Growth
- CGNT 11.88
- PHAR 24.13
- 52 Week Low
- CGNT $6.21
- PHAR $6.65
- 52 Week High
- CGNT $11.12
- PHAR $11.07
- Technical
- Relative Strength Index (RSI)
- CGNT 73.28
- PHAR 69.45
- Support Level
- CGNT $9.76
- PHAR $8.69
- Resistance Level
- CGNT $10.99
- PHAR $10.00
- Average True Range (ATR)
- CGNT 0.36
- PHAR 0.33
- MACD
- CGNT 0.09
- PHAR 0.09
- Stochastic Oscillator
- CGNT 95.74
- PHAR 100.00
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.